Literature DB >> 34674228

Inference in response-adaptive clinical trials when the enrolled population varies over time.

Massimiliano Russo1, Steffen Ventz2, Victoria Wang2, Lorenzo Trippa2.   

Abstract

A common assumption of data analysis in clinical trials is that the patient population, as well as treatment effects, do not vary during the course of the study. However, when trials enroll patients over several years, this hypothesis may be violated. Ignoring variations of the outcome distributions over time, under the control and experimental treatments, can lead to biased treatment effect estimates and poor control of false positive results. We propose and compare two procedures that account for possible variations of the outcome distributions over time, to correct treatment effect estimates, and to control type-I error rates. The first procedure models trends of patient outcomes with splines. The second leverages conditional inference principles, which have been introduced to analyze randomized trials when patient prognostic profiles are unbalanced across arms. These two procedures are applicable in response-adaptive clinical trials. We illustrate the consequences of trends in the outcome distributions in response-adaptive designs and in platform trials, and investigate the proposed methods in the analysis of a glioblastoma study.
© 2021 The International Biometric Society.

Entities:  

Keywords:  adaptive trial design; bootstrap; glioblastoma; platform trials; population trends; splines

Year:  2021        PMID: 34674228      PMCID: PMC9021332          DOI: 10.1111/biom.13582

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   1.701


  25 in total

1.  Analysis of time trends in adaptive designs with application to a neurophysiology experiment.

Authors:  F Hu; W F Rosenberger
Journal:  Stat Med       Date:  2000-08-15       Impact factor: 2.373

2.  Semiparametric models: a generalized self-consistency approach.

Authors:  A Tsodikov
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2003-08-01       Impact factor: 4.488

3.  Assumptions in Clinical Trial Designs and Therapies.

Authors:  Richard I Shader
Journal:  Clin Ther       Date:  2018-11-03       Impact factor: 3.393

4.  Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.

Authors:  P Thall; P Fox; J Wathen
Journal:  Ann Oncol       Date:  2015-05-15       Impact factor: 32.976

5.  Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.

Authors:  Steffen Ventz; Matteo Cellamare; Giovanni Parmigiani; Lorenzo Trippa
Journal:  Biostatistics       Date:  2018-04-01       Impact factor: 5.899

6.  Enrollment bias: frequency and impact on patient selection in endovascular stroke trials.

Authors:  Sunil A Sheth; Jeffrey L Saver; Sidney Starkman; Ileana D Grunberg; Judy Guzy; Latisha K Ali; Doojin Kim; Nestor R Gonzalez; Reza Jahan; Satoshi Tateshima; Gary Duckwiler; David S Liebeskind
Journal:  J Neurointerv Surg       Date:  2015-02-19       Impact factor: 5.836

Review 7.  Practical Bayesian adaptive randomisation in clinical trials.

Authors:  Peter F Thall; J Kyle Wathen
Journal:  Eur J Cancer       Date:  2007-02-16       Impact factor: 9.162

8.  Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial.

Authors:  Jordan J Elm; Yuko Y Palesch; Gary G Koch; Vanessa Hinson; Bernard Ravina; Wenle Zhao
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

9.  MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents.

Authors:  Ying Yuan; Beibei Guo; Mark Munsell; Karen Lu; Amir Jazaeri
Journal:  Stat Med       Date:  2016-04-25       Impact factor: 2.373

10.  Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?

Authors:  Sofía S Villar; Jack Bowden; James Wason
Journal:  Pharm Stat       Date:  2017-12-19       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.